Cellistic And Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including existing facility and all related personnel.
Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic™'s expertise in iPSC cell therapy platform development and scale-up
Ncardia Launches Cellistic™ — Purpose-Built To Make Large-Scale Allogeneic Cell Therapy Production A Reality Today
Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.